Loading...
Header Logo
Keywords
Last Name
Institution

LUCA MALORNI

TitleClinical Assistant Professor
InstitutionBaylor College of Medicine
DepartmentBreast Center
DivisionBreast Cancer Center
vCardDownload vCard
    Other Positions
    TitleClinical Assistant Professor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Hematology & Oncology


    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). Eur J Cancer. 2019 Jun; 114:55-66. PMID: 31059974.
      View in: PubMed
    2. Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A. The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treat Rev. 2019 Mar; 74:29-34. PMID: 30708267.
      View in: PubMed
    3. Romagnoli D, Boccalini G, Bonechi M, Biagioni C, Fassan P, Bertorelli R, De Sanctis V, Di Leo A, Migliaccio I, Malorni L, Benelli M. ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. BMC Genomics. 2018 Dec 24; 19(1):960. PMID: 30583719.
      View in: PubMed
    4. Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A. Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence? Ther Adv Med Oncol. 2018; 10:1758835918815591. PMID: 30574210.
      View in: PubMed
    5. Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, De Angelis C, Di Leo A, Malorni L, Migliaccio I. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer. 2018; 4:38. PMID: 30511015.
      View in: PubMed
    6. McCartney A, Di Leo A, Malorni L. Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction? Oncotarget. 2018 Sep 25; 9(75):34031-34032. PMID: 30344918.
      View in: PubMed
    7. Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L. Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Res. 2018 Aug; 38(8):4839-4845. PMID: 30061257.
      View in: PubMed
    8. McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A. The role of abemaciclib in treatment of advanced breast cancer. Ther Adv Med Oncol. 2018; 10:1758835918776925. PMID: 29899762.
      View in: PubMed
    9. Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018 Mar 27; 9(23):16389-16399. PMID: 29662653.
      View in: PubMed
    10. Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. Breast Cancer Res Treat. 2018 Jul; 170(2):329-341. PMID: 29564743.
      View in: PubMed
    11. Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M. First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast. 2018 Apr; 38:144-149. PMID: 29324303.
      View in: PubMed
    12. Guarducci C, Bonechi M, Boccalini G, Benelli M, Risi E, Di Leo A, Malorni L, Migliaccio I. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care (Basel). 2017 Oct; 12(5):304-308. PMID: 29234249.
      View in: PubMed
    13. Malorni L, Biganzoli L. Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer? Breast Care (Basel). 2017 Oct; 12(5):288-289. PMID: 29234246.
      View in: PubMed
    14. Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016 09 13; 7(42):68012-68022. PMID: 27634906.
      View in: PubMed
    15. Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5755-5764. PMID: 27185372.
      View in: PubMed
    16. Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81. PMID: 26965145.
      View in: PubMed
    17. Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A. A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. NPJ Breast Cancer. 2015; 1:15003. PMID: 28721363.
      View in: PubMed
    18. Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015 Sep; 12(9):541-52. PMID: 26011489.
      View in: PubMed
    19. Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. New approaches for improving outcomes in breast cancer in Europe. Breast. 2015 Aug; 24(4):321-30. PMID: 25840656.
      View in: PubMed
    20. Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med. 2015 Mar 05; 13:46. PMID: 25857348.
      View in: PubMed
    21. Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015 Apr; 9(4):749-57. PMID: 25539732.
      View in: PubMed
    22. Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol. 2014 Nov; 26(6):568-75. PMID: 25188473.
      View in: PubMed
    23. Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel). 2014 Mar 25; 6(2):684-707. PMID: 24670368.
      View in: PubMed
    24. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014 Jan; 106(1):djt337. PMID: 24317176.
      View in: PubMed
    25. Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. The continued evidence from overviews: what is the clinical utility? Breast. 2013 Aug; 22 Suppl 2:S8-11. PMID: 24074798.
      View in: PubMed
    26. Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Adjuvant chemotherapy: which patient? What regimen? Am Soc Clin Oncol Educ Book. 2013; 3-8. PMID: 23714442.
      View in: PubMed
    27. Di Leo A, Malorni L. Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol. 2012 Jun 01; 30(16):1897-900. PMID: 22547606.
      View in: PubMed
    28. Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60. PMID: 19924529.
      View in: PubMed
    29. Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. 2009 Oct 08; 28:135. PMID: 19814782.
      View in: PubMed
    30. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501. PMID: 18794137.
      View in: PubMed
    31. De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erreni M, Pelicci G, Santoro M, Melillo RM. RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. Oncogene. 2005 Sep 15; 24(41):6303-13. PMID: 15940252.
      View in: PubMed
    32. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4741-8. PMID: 16000569.
      View in: PubMed
    33. Castellone MD, Cirafici AM, De Vita G, De Falco V, Malorni L, Tallini G, Fagin JA, Fusco A, Melillo RM, Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene. 2003 Jan 16; 22(2):246-55. PMID: 12527893.
      View in: PubMed
    MALORNI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description